EP Patent

EP2101779A1 — Medical implants with a combination of compounds

Assigned to Angiotech Pharmaceuticals Inc · Expires 2009-09-23 · 17y expired

What this patent protects

Implants are associated with a combination of paclitaxel or derivatives and dipyridamole or derivatives in order to inhibit fibrosis that may otherwise occur when the implant is placed within an animal. Exemplary implants include intravascular implants (e.g., coronary and periphe…

USPTO Abstract

Implants are associated with a combination of paclitaxel or derivatives and dipyridamole or derivatives in order to inhibit fibrosis that may otherwise occur when the implant is placed within an animal. Exemplary implants include intravascular implants (e.g., coronary and peripheral vascular stents, catheters, balloons), non-vascular stents, pumps and sensors, vascular grafts, perivascular devices, implants for hemodialysis access, vena cava filters, implants for providing an anastomotic connection, electrical devices, intraocular implants, and soft tissue implants and fillers.

Drugs covered by this patent

Patent Metadata

Patent number
EP2101779A1
Jurisdiction
EP
Classification
—
Expires
2009-09-23
Drug substance claim
No
Drug product claim
No
Assignee
Angiotech Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.